Sebetralstat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sebetralstat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
9
Registered trials
19
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sebetralstat can convert its Small molecule drug profile and KLKB1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sebetralstat (query alias: sebetralstat) |
|---|---|
| Modality / target | Small molecule drug; KLKB1; KLKB1 inhibitors |
| Highest global status | Approved |
| Originator | Vantia Ltd. |
| Active developers | KalVista Pharmaceuticals Ltd., KalVista Pharmaceuticals, Inc., KalVista Pharmaceuticals (Ireland) Ltd. |
The MCP disease footprint includes Hereditary Angioedema, Hematologic Diseases, Hereditary Angioedema Types I and II. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07654829 | Phase 4 | Not yet recruiting | 100 | The number and proportion of STPs that did not result in an HAE attack within 24 hours after the start of the procedure will be summarized. |
| NCT06467084 | Phase 3 | Completed | 36 | The proportion of pediatric patients with HAE Types I or II who take any sebetralstat dose, who experience any AE(s) (including fatal AEs) during the study, irrespective of uses of other medications and sebetralstat discontinuations for any reason. |
| NCT07216378 | Not Applicable | Available | Not disclosed | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials
Phase 2/3; n=377; evaluation: Positive. Reported fields: AE = Sebetralstat had a safety profile comparable to placebo. ; AE = Sebetralstat had a safety profile comparable to placebo. ; AE = Sebetralstat had a safety profile comparable to placebo.
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
Phase 3; n=84; evaluation: Positive. Reported fields: Time to complete resolution = 21.02 hour
Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S
Phase 3; n=198; evaluation: Positive. Reported fields: TEAE = 91.0 Pts ; TEAE = 14.0 Pts
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sebetralstat addresses Hereditary Angioedema, Hematologic Diseases, Hereditary Angioedema Types I and II. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-01-08 | Multicare Pharma signed an exclusive agreement to commercialize KalVista Pharmaceuticals ' Ekterly (sebetralstat) against hereditary angioedema (HAE) in Latin America, including Brazil, Argentina, Colombia and Mexico | Approved | Financial terms not disclosed |
| 2025-07-07 | Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat) | Approved | Financial terms not disclosed |
| 2025-06-26 | KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada | NDA/BLA | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Sebetralstat for the treatment of anxiety associated with hereditary angioedema”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
